News & Events

Rockville, MD (May 23, 2008) – BD Biosciences announced today the launch of BD AttoVision™ software v1.6 that enhances the analysis of cellular image data from BD Pathway™ bioimaging systems.

“The release of BD AttoVision software v1.6 demonstrates our commitment to ensuring cellular researchers get the most from their BD Pathway bioimagers,” said Tom Driscoll, Vice President, Bioimaging.“The software’s advanced image analysis features, coupled with its newly designed user interface, enables our customers to enhance the quality and efficiency of their experiments.”

This advanced software simplifies image acquisition and analysis of complex and demanding experiments, while enabling researchers to maintain the flexibility they value in BD Pathway systems.Its new features include:

• Image preprocessing and segmentation filters that enhance the ability to extract or identify cells or cellular regions
• Faster, more accurate object splitting for small spots or objects
• Band segmentation outputs, including erosion of the nuclear region, for improved signal/noise
• Measurement features that expand the ability to analyze and characterize cellular and subcellular regions or phenotypes

BD AttoVision software v1.6 also provides a customizable workspace that allows researchers to create workspace layouts that meet the needs of their specific experiments and workflow.Experimental results and images may be quickly reviewed and linked together, allowing the user to zoom in/out or pan simultaneously.

“The new software is used exclusively with BD Pathway™ bioimaging instruments that, along with BD’s line of flow cytometry instruments and bioimaging certified reagents, positions BD as a true leader in cellular analysis,” said Driscoll.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

###